News | October 23, 2022
Glenmark Life Sciences Q2FY23 PAT slips to Rs. 106.87 Cr
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
The company has reported total income of Rs. 519.31 crores during the period ended September 30, 2022.
A well researched and affordable fixed dose combination, which will significantly improve the glycemic control in adult patients suffering from uncontrolled Type 2 diabetes, especially the ones with comorbidities
CHMP positive opinion is based on evidence from the EFFISAYIL trial, the largest clinical trial in
Availability of pharmaceutical-grade materials with broad API compatibility key to advancing drug delivery solutions
Plans to double its manufacturing footprint to bolster the growth
Glenmark is the first company in India to launch Thiazolidinedione Lobeglitazone (0.5 mg).
There is also a growing interest in whole generation sequencing (WGS)
RYALTRIS is a fixed-dose combination therapy that provides relief for the symptoms of SAR, both nasal and ocular, in one easy-to-use nasal spray
The country has been witnessing a progressive reduction in IMR, U5MR and NMR
Charsire Biotechnology Corp. has successfully developed a revolutionary new drug (BAC) for Alzheimer's disease
Subscribe To Our Newsletter & Stay Updated
